BEHAVOX
16.5.2022 15:05:13 CEST | Business Wire | Press release
Behavox , which provides a suite of security products that help compliance, HR, and security teams protect their company and colleagues from bad actors, today announced that its academic research paper on artificial intelligence “Continual learning using lattice-free MMI for speech recognition” has been accepted by the International Conference on Acoustics, Speech, and Signal Processing (ICASSP). ICASSP is the world's largest and most comprehensive technical conference focused on signal processing and its applications. Behavox presented this paper in Singapore for IEEE ICASSP 2022 on May 9, 2022.
“Sometimes scientists do research for science’s sake and society is unlikely to see benefits in the near future. In contrast, we pushed science to a new frontier to find a solution to a current problem,” said Behavox CTO Joseph Benjamin. “We are honored to have received recognition from such a prestigious conference and are very proud of our team and the work they did.”
The paper, written by Behavox’s Machine Learning team, addresses challenges of continuously improving speech recognition systems in privacy-preserving settings. This research directly links to Behavox’s R&D approach for providing customers with the best transcription quality in the financial market. In FinTech, the language and the data that Behavox systems have to reliably process rapidly change over time, with the rise of cryptocurrencies and video communications being but two examples.
Consequently, machine learning models must be frequently updated on relevant data. To make such updates possible without undermining data privacy, the model should be able to gradually improve inside secure client environments without access to historical data and data from other customers. This is a challenging problem in machine learning due to catastrophic forgetting, where after improving on a specific type of data, the model starts to perform badly on previously learned data.
The Behavox ICASSP paper contributes to the field of continual learning for speech recognition. Authors propose a novel algorithm that extends and refines the commonly used Learning Without Forgetting (LWF) technique, which relies on a regularization term and forces neural networks to reduce forgetting. More specifically, the authors designed a novel sequence level neural network training loss that can be used instead of conventional point-wise LWF. They demonstrated a significant reduction of forgetting when the neural network is fine-tuned sequentially on various accents and speech styles.
Behavox has found that the use of voice platforms has increased 94 percent year-over-year and that on average almost a third of all workplace communications take place via phone or video conference calls.
This technique has already been successfully applied to its Danish system, where the collaborative work of Behavox linguists, the machine learning team, and a customer allowed Behavox to build its first Danish transcription system that reliably works on banking data.
About Behavox
Behavox provides a suite of security products that help compliance, HR, and security teams protect their company and colleagues from bad actors.
Through AI-powered analysis of all corporate communications data, including email, instant messaging, voice, and video conferencing platforms, Behavox helps organizations identify illegal, immoral, and malicious behavior in the workplace.
Founded in 2014, Behavox is headquartered in Montreal and has offices in New York City, London, Seattle, Singapore, and Tokyo.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220513005069/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
